Geron Co. (NASDAQ:GERN) Short Interest Down 5.4% in November

Geron Co. (NASDAQ:GERNGet Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 66,350,000 shares, a decrease of 5.4% from the November 15th total of 70,130,000 shares. Based on an average trading volume of 8,070,000 shares, the days-to-cover ratio is presently 8.2 days.

Analyst Ratings Changes

Several brokerages recently issued reports on GERN. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a research report on Tuesday, December 10th. Scotiabank began coverage on shares of Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective for the company. Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Leerink Partnrs raised Geron to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Leerink Partners started coverage on Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron currently has a consensus rating of “Moderate Buy” and an average price target of $7.15.

View Our Latest Report on GERN

Hedge Funds Weigh In On Geron

Institutional investors have recently bought and sold shares of the business. Alternative Investment Advisors LLC. boosted its stake in shares of Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 2,612 shares during the period. Arizona State Retirement System lifted its holdings in Geron by 3.1% during the 2nd quarter. Arizona State Retirement System now owns 115,400 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 3,465 shares during the last quarter. Values First Advisors Inc. boosted its position in Geron by 13.6% during the third quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 3,668 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Geron by 23.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,094 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Trading Down 1.3 %

Shares of Geron stock opened at $3.81 on Tuesday. The stock has a market cap of $2.30 billion, a P/E ratio of -11.91 and a beta of 0.51. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The business’s 50 day moving average is $4.06 and its 200-day moving average is $4.36.

Geron (NASDAQ:GERNGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) earnings per share. Equities research analysts predict that Geron will post -0.25 earnings per share for the current fiscal year.

Geron Company Profile

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Featured Articles

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.